Corpus overview


Overview

MeSH Disease

Human Phenotype

Pneumonia (19)

Hypertension (17)

Fever (9)

Cough (7)

Obesity (7)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 85
    records per page




    The Coronavirus Disease Pandemic MESHD 2019 [COVID-19]: Impact on NHS England PET-CT Scanning 

    Authors: Wai Lup Wong; Peter Ross; Kevin Peters; Marion Frenz; Tong Hai; Alex Ridgeon; Ralph Toop; Peter Strouhal; Jimmy Bomanji

    doi:10.21203/rs.3.rs-77635/v1 Date: 2020-09-14 Source: ResearchSquare

    Purpose To examine the impact of the COVID-19 pandemic on PET-CT scanning activity across England.  Methods Monthly PET-CT scanning activity was collected from 41/48 NHS England provider sites. Data from 31/41sites was stratified by non-oncology/oncology and cancer type. Lung c ancer MESHDand lymphoma HP ymphoma MESHDactivity was split into specific indications. The data was compiled in Excel and analysed using Stata software to assess distribution and statistical significance of variation in activity comparing levels before and during the COVID-19 pandemic. Results In April and May 2020 a 32% and 31% decrease in activity was observed; a larger decrease for n on-cancer MESHDcompared with c ancer MESHDPET-CT. In June 2020 PET-CT activity started to recover with 6% fewer scans recorded compared with June 2019. Decrease and recovery varied according to c ancer MESHDtypes. Of the six most common indications for PET CT, l ung and oesophageal cancer MESHDhad the largest decrease in activity: lung -29%, -45% and oesophagus -43%, -59% in April and May respectively, and slowest recovery, -23%, -26% respectively in June. By contrast, lymphoma HP ymphoma MESHDand melanoma HP elanoma MESHDshowed the smallest decrease: lymphoma HP ymphoma MESHD-14%, -9%; melanoma HP elanoma MESHD-16%, +5% in April and May respectively, and fastest recovery +12% lymphoma HP ymphoma MESHD+14% respectively. Specifically, l ung cancer MESHDPET-CTs related to initial diagnosis and staging saw the largest fall HP and slowest recovery compared with PET-CTs for people with known l ung cancer. MESHD Conclusions There was considerable variation in the rate of decline and recovery in PET-CT scanning across c ancer MESHDtypes and specific indications related to the cancer type. The causes for the variation remain to be explained. 

    No association between circulating levels of testosterone and sex hormone-binding globulin and risk of COVID-19 mortality in UK biobank

    Authors: Xikang Fan; Jing Yang; Jiayu Wang; Cheng Yin; Meng Zhu; Hongxia Ma; Guangfu Jin; Zhibin Hu; Hongbing Shen; Dong Hang; Roland M. Schmid; Tobias Lahmer; Wolfgang Huber; Xiushan Yin; Arsen Arakelyan; Denise Haslwanter; Rohit Jangra; Alev Celikgil; Duncan Kimmel; James H Lee; Margarette Mariano; Antonio Nakouzi; Jose Quiroz; Johanna Rivera; Wendy A Szymczak; Karen Tong; Jason Barnhill; Mattias NE Forsell; Clas Ahlm; Daniel T. Stein; Liise-anne Pirofski; Doctor Y Goldstein; Scott J. Garforth; Steven C. Almo; Johanna P. Daily; Michael B. Prystowsky; James D. Faix; Amy S. Fox; Louis M. Weiss; Jonathan R. Lai; Kartik Chandran

    doi:10.1101/2020.09.11.20191783 Date: 2020-09-11 Source: medRxiv

    Background: Sex-disaggregated data suggest that men with coronavirus disease MESHD 2019 (COVID-19) are more likely to die than women. Whether circulating testosterone or sex hormone-binding globulin (SHBG) contributes to such sex differences remains unknown. Objective: To evaluate the associations of circulating total testosterone (TT), free testosterone (FT), and SHBG with COVID-19 mortality. Design: Prospective analysis. Setting: UK Biobank. Participants: We included 1306 COVID-19 patients (678 men and 628 women) who had serum SERO TT and SHBG measurements and were free of cardiovascular disease MESHD or cancer MESHD at baseline (2006-2010). Main outcome measures: The death cases of COVID-19 were identified from National Health Service death records updated at 31 July 2020. Unconditional logistic regression was performed to estimate the odds ratio (OR) and 95% confidence intervals (CI) for mortality. Results: We documented 315 deaths of COVID-19 (194 men and 121 women). After adjusting for potential confounders, we did not find any statistically significant associations for TT (OR per 1-SD increase = 1.03, 95% CI: 0.85-1.25), FT (OR per 1-SD increase = 0.95, 95% CI: 0.77-1.17), or SHBG (OR per 1-SD increase = 1.09, 95% CI: 0.87-1.37) with COVID-19 mortality in men. Similar null results were observed in women (TT: OR per 1-SD increase = 1.10, 95% CI: 0.85-1.42; FT: OR per 1-SD increase = 1.10, 95% CI: 0.82-1.46; SHBG: OR per 1-SD increase = 1.16, 95% CI: 0.89-1.53). Conclusions: Our findings do not support a significant role of circulating testosterone or SHBG in COVID-19 prognosis.

    COVID-19 Biomarkers in research: Extension of the OncoMX cancer MESHD biomarker data model to capture biomarker data from other diseases.

    Authors: Nikhita Gogate; Daniel Lyman; Keith A Crandall; Robel Kahsay; Darren A. Natale; Sabyasachi Sen; Raja Mazumder; Tongqing Zhou; Shilei Ding; Romain Gasser; Jeremie Prevost; Guillaume Beaudoin-Bussieres; Sai Priya Anand; Annemarie Laumaea; Jonathan R. Grover; Liu Lihong; David D Ho; John Mascola; Andres Finzi; Peter D. Kwong; Walther Mothes

    doi:10.1101/2020.09.09.196220 Date: 2020-09-10 Source: bioRxiv

    Scientists, medical researchers, and health care workers have mobilized worldwide in response to the outbreak of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2; SCoV2). Preliminary data have captured a wide range of host responses, symptoms, and lingering problems post-recovery within the human population. These variable clinical manifestations suggest differences in influential factors, such as innate and adaptive host immunity, existing or underlying health conditions, co-morbidities, genetics, and other factors. As COVID-19-related data continue to accumulate from disparate groups, the heterogeneous nature of these datasets poses challenges for efficient extrapolation of meaningful observations, hindering translation of information into clinical applications. Attempts to utilize, analyze, or combine biomarker datasets from multiple sources have shown to be inefficient and complicated, without a unifying resource. As such, there is an urgent need within the research community for the rapid development of an integrated and harmonized COVID-19 Biomarker Knowledgebase. By leveraging data collection and integration methods, backed by a robust data model developed to capture cancer MESHD biomarker data we have rapidly crowdsourced the collection and harmonization of COVID-19 biomarkers. Our resource currently has 138 unique biomarkers. We found multiple instances of the same biomarker substance being suggested as multiple biomarker types during our extensive cross-validation and manual curation. As a result, our Knowledgebase currently has 265 biomarker type combinations. Every biomarker entry is made comprehensive by bringing in together ancillary data from multiple sources such as biomarker accessions (canonical UniProtKB accession, PubChem Compound ID, Cell Ontology ID, Protein Ontology ID, NCI Thesaurus Code, and Disease Ontology ID), BEST biomarker category, and specimen type (Uberon Anatomy Ontology) unified with ontology standards. Our preliminary observations show distinct trends in the collated biomarkers. Most biomarkers are related to the immune system (SAA,TNF-{propto}, and IP-10) or coagulopathies MESHD (D-dimer, antithrombin, and VWF) and a few have already been established as cancer MESHD biomarkers (ACE2, IL-6, IL-4 and IL-2). These trends align with proposed hypotheses of clinical manifestations compounding the complexity of COVID-19 pathobiology. We explore these trends as we put forth a COVID-19 biomarker resource that will help researchers and diagnosticians alike. All biomarker data are freely available from https://data.oncomx.org/covid19.

    Low-dose Whole-lung Irradiation for COVID-19 Pneumonia HP: What is the Optimal Dose? Final Results of a Pilot Study

    Authors: Ahmad Ameri; Pooya Ameri; Nazanin Rahnama; Majid Mokhtari; Meghdad Sedaghat; Fahimeh Hadavand; Rama Bozorgmehr; Mehrdad Haghighi; Farzad Taghizadeh-Hesary

    id:10.20944/preprints202009.0229.v1 Date: 2020-09-10 Source: Preprints.org

    Purpose: Novel coronavirus disease MESHD (COVID-19) is the current global concern. Radiotherapy (RT), commonly employed in cancer MESHD management, has been considered one of the potential treatments for COVID-19 pneumonia HP pneumonia MESHD. Here, we present the final report of the pilot trial evaluating the efficacy and safety of low-dose whole-lung irradiation (LD-WLI) in patients with COVID-19 pneumonia HP pneumonia MESHD. Methods and Materials: We enrolled patients with moderate COVID-19 pneumonia HP pneumonia MESHD who were older than 60 years. Participants were treated with LD-WLI in a single fraction of 0.5 or 1.0Gy along with the national protocol of COVID-19. The primary endpoints were improvement of SpO2, the number of hospital/ICU stay days, and the number of intubations after RT and the secondary endpoints were alterations of the c-reactive peptide, interleukin-6, ferritin, procalcitonin, and D-dimer. The response rate (RR) was defined as a rise in SpO2 upon RT with rising or constant trend in the next two days, and clinical recovery (CR) included patients who were discharged from the hospital or acquired SpO2 ≥93% on room air. Results: Between 21 May 2020 and 2 July 2020, ten patients were enrolled. The median age TRANS was 75 years, 80% were male TRANS, and 80% had comorbidities. The first five patients received a single 0.5Gy-WLI, and others received 1.0Gy. Patients were followed for 2-14 days (median 5.5 days). Following one day, nine patients experienced an improvement in SpO2. Five patients were discharged (median 6th day, range 2nd-14th day), and four patients died (median 7th day, range 3rd-10th day). Overall, the RR and CR were 60.0% and 55.5%, respectively. The RR and CR rates of 0.5- and 1.0Gy group were 80% vs 40% and 75% vs 40%, respectively. No acute radiation-induced toxicity MESHD was recorded. Conclusions: LD-WLI with a single 0.5Gy fraction seems to be a more appropriate dose to warrant further evaluation in a large-scale, randomized trial.

    Burden and prevalence SERO of risk factors for severe COVID-19 disease in the ageing European population – A SHARE-based analysis

    Authors: Linda Juel Ahrenfeldt; Camilla Riis Nielsen; Sören Möller; Kaare Christensen; Rune Lindahl-Jacobsen

    doi:10.21203/rs.3.rs-73657/v1 Date: 2020-09-07 Source: ResearchSquare

    Aim: International health authorities suggest that individuals aged TRANS 65 years and above and people with underlying comorbidities such as hypertension HP hypertension MESHD, chronic lung disease HP lung disease MESHD, cardiovascular disease MESHD, cancer MESHD, diabetes MESHD, and obesity HP obesity MESHD are at increased risk of severe Coronavirus Disease MESHD 2019 (COVID-19); however, the prevalence SERO of risk factors is unknown in many countries. Therefore, we aim to describe the distribution of these risk factors across Europe. Subject and Methods: Prevalence SERO of risk factors for severe COVID-19 was identified based on interview for 73,274 Europeans aged TRANS 50+ participating in the Survey of Health, Ageing and Retirement in Europe (SHARE) in 2017. Burden of disease was estimated using population data from Eurostat. Results: A total of 75.3% of the study population (corresponding to app. 60 million European men and 71 million women) had at least one risk factor for severe COVID-19, 45.9% (app. 36 million men and 43 million women) had at least two factors and 21.2% (app. 17 million men and 20 million women) had at least three risk factors. The prevalences SERO of underlying medical conditions ranged from 4.5% for cancer MESHD to 41.4% for hypertension HP hypertension MESHD, and the region-specific prevalence SERO of having at least three risk factors ranged from 18.9% in Northern Europe to 24.6% in Eastern Europe. Conclusions: Information about the prevalences SERO of risk factors might help authorities to identify the most vulnerable subpopulations with multiple risk factors of severe COVID-19 disease MESHD and thus to decide appropriate strategies to mitigate the pandemic.  

    On Cancer, COVID-19 and CT Scan: A Monocentric Retrospective Study

    Authors: Francesca Martini; Andrea D'Alessio; Federico Bracchi; Daniela Di Mauro; Anna Fargnoli; Marco Motta; Cristina Giussani; Marco Meazza Prina; Giovanni Gobbin; Monica Taverna

    id:10.20944/preprints202009.0075.v1 Date: 2020-09-04 Source: Preprints.org

    Background The acknowledgment of computed tomography (CT) defined diagnosis in high prevalence SERO northern Italy may identify more patients with Coronavirus Disease MESHD-2019 (COVID 19) infection MESHD, than RT-PCR alone. Methods We retrospectively reviewed 148 chest CT scans of oncological patients who were referred to the Radiological Unit of Policlinico S. Marco from 1st of February 2020 to 30th of April 2020, during the Covid-19 outbreak in Bergamo area. Therefore, we analyzed RT-PCR tests of these 148 patients. Results Among 32 patients with diagnosis of COVID-19 infection MESHD: 17 patients were asymptomatic TRANS or had mild symptoms (53.1%), while 15 developed severe disease (46.8%). The incidence of COVID-19 infection MESHD is 22.9%, the mortality rate is 18.8%. Severe COVID-19 disease is associated with higher median age TRANS. We did not find any correlation between disease severity and sex, smoke or cardiovascular comorbidities. Remarkably, patients who were on treatment developed milder disease MESHD than cancer MESHD patients who were not on treatment. Conclusions The acceptance of CT-defined diagnosis in high prevalence SERO area like Bergamo highlighted a larger number of COVID-19 oncological population than RT-PCR alone, in particular asymptomatic TRANS and mild symptomatic patients. We observed that actively treated patients had milder disease, according to previous studies that suggested a protective role of immunosuppression.

    healthcareCOVID: A national cross-sectional observational study identifying risk factors for developing suspected or confirmed COVID-19 in UK healthcare workers

    Authors: Justin Kua; Reshma Patel; Eveliina Nurmi; Sarah Tian; Harpreet Gill; Calvin Moorley; Danny JN Wong; Dmitri Nepogodiev; Imran Ahmad; Kariem El-Boghdadly; Josephine Soltani; Mehrsa Koukabi-Fradelizi; Jean Paul Beressi; Cecile Laureana; Jean Fran&ccedilois Prost; Livarek Bernard; Elisabet Leiva; Albert Ariza-Sole; Paolo D Dallaglio; Maria Quero; Antonio Soriano; Alberto Pasqualetto; Maylin Koo; Virginia Esteve; Arnau Antoli; Rafael Moreno; Sergi Yun; Pau Cerda; Mariona Llaberia; Francesc Formiga; Marta Fanlo; Abelardo Montero; David Chivite; Olga Capdevila; Ferran Bolao; Xavier Pinto; Josep Llop; Antoni Sabate; Jordi Guardiola; Josep M Cruzado; Josep Comin-Colet; Salud Santos; Ramon Jodar; Xavier Corbella

    doi:10.1101/2020.08.28.20182295 Date: 2020-09-01 Source: medRxiv

    Objective To establish the prevalence SERO and risk factors for the development of suspected or confirmed coronavirus disease MESHD 2019 (COVID-19) infection among healthcare workers (HCWs) in the United Kingdom (UK). Design Cross-sectional observational study. Setting UK-based primary and secondary care. Participants HCWs aged TRANS [≥]18 years working between 1 February and 25 May 2020. Main outcome measures A composite endpoint of laboratory-confirmed diagnosis of SARS-CoV-2, or self-isolation or hospitalisation due to suspected or confirmed COVID-19. Results Of 6152 eligible responses, the composite endpoint was present in 1806 (29.4%) HCWs, of whom 49 (0.8%) were hospitalised, 459 (7.5%) tested positive for SARS-CoV-2, and 1776 (28.9%) reported self-isolation. The strongest risk factor associated with the presence of the primary composite endpoint was increasing frequency of contact TRANS frequency of contact SERO with suspected or confirmed COVID-19 cases without adequate personal protective equipment (PPE): ''Never'' (reference), ''Rarely'' (adjusted odds ratio 1.06, (95% confidence interval: 0.87 to 1.29)), ''Sometimes'' (1.7 (1.37 to 2.10)), ''Often'' (1.84 (1.28 to 2.63)), ''Always'' (2.93, (1.75 to 5.06)). Additionally, several comorbidities ( cancer MESHD, respiratory disease MESHD, and obesity HP obesity MESHD); working in a 'doctors' role; using public transportation for work; regular contact with suspected or confirmed COVID-19 patients; and lack of PPE were also associated with the presence of the primary endpoint. 1382 (22.5%) HCWs reported lacking access to PPE items while having clinical contact with suspected or confirmed COVID-19 cases. Overall, between 11,870 and 21,158 days of self-isolation were required by the cohort, equalling approximately 71 to 127 working days lost per 1000 working days. Conclusions Suspected or confirmed COVID-19 was more common in HCWs than in the general population. Risk factors included inadequate PPE, which was reported by nearly a quarter of HCWs. Governments and policymakers must ensure adequate PPE is available as well as developing strategies to mitigate risk for high-risk HCWs during future COVID-19 waves.

    Impact of hematologic malignancy MESHD and type of cancer MESHD therapy on COVID-19 severity and mortality: lessons from a large population-based registry study

    Authors: Julio García-Suárez*; Javier de la Cruz*; Ángel Cedillo; Pilar Llamas; Rafael Duarte; Víctor Jiménez-Yuste; José Ángel Hernández-Rivas; Rodrigo Gil-Manso; Mi Kwon; Pedro Sánchez-Godoy; Pilar Martínez-Barranco; Blanca Colás-Lahuerta; Pilar Herrera; Laurentino Benito-Parra; Adrián Alegre; Alberto Velasco; Arturo Matilla; María Concepción Aláez-Usón; Rafael Martos-Martínez; Carmen Martínez-Chamorro; Keina Susana-Quiroz; Juan Francisco Del Campo; Adolfo de la Fuente; Regina Herráez; Adriana Pascual; Elvira Gómez; Jaime Pérez-Oteyza; Elena Ruiz; Arancha Alonso; José González-Medina; Lucía Núñez Martín-Buitrago; Miguel Canales; Isabel González-Gascón; María Carmen Vicente-Ayuso; Susana Valenciano; María García Roa; Pablo Estival Monteliu; Javier López-Jiménez; Cristián Escolano Escobar; Javier Ortiz-Martín; José Luis Diez-Martin†; Joaquín Martínez-López†

    doi:10.21203/rs.3.rs-69133/v1 Date: 2020-08-31 Source: ResearchSquare

    Background Patients with cancer MESHD have been shown to have a higher risk of clinical severity and mortality compared to non-cancer MESHD patients with COVID-19. Patients with hematologic malignancies MESHD typically are known to have higher levels of immunosuppression and may develop more severe respiratory viral infections MESHD than patients with solid tumours MESHD. Data on COVID-19 in patients with hematologic malignancies MESHD are limited. Here we characterise disease severity and mortality, and evaluate potential prognostic factors for mortality.Methods In this population-based registry study, we collected de-identified data on clinical characteristics, treatment and outcomes in adult TRANS patients with hematologic malignancies MESHD and confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection MESHD within the Madrid region of Spain. Our case series included all patients admitted to 22 regional health service hospitals and 5 private healthcare centres between February 28 and May 25, 2020. The primary study outcome was all-cause mortality. We assessed the association between mortality and potential prognostic factors using Cox regression analyses adjusted for age TRANS, sex, comorbidities, hematologic malignancy MESHD and recent active cancer MESHD therapy.Results Of 833 patients reported, 697 were included in the analyses. Median age TRANS was 72 years (IQR 60–79), 413 (60%) patients were male TRANS, and 479 (69%) and 218 (31%) had lymphoid MESHD and myeloid malignancies, respectively. Clinical severity of COVID-19 was severe/critical in 429 (62%) patients. At data cutoff, 230 (33%) patients had died. Age TRANS ≥60 years (hazard ratios 3·17–10·1 vs <50 years), >2 comorbidities (1·41 vs ≤2), acute myeloid leukemia HP acute myeloid leukemia MESHD (2·22 vs non-Hodgkin lymphoma HP lymphoma MESHD) and active antineoplastic treatment with monoclonal antibodies SERO (2·02) or conventional chemotherapy (1·50 vs no active therapy) were associated with increased mortality. Conversely, Ph-negative myeloproliferative neoplasms MESHD neoplasms HP (0·33) and active treatment with hypomethylating agents (0·47) were associated with lower mortality. Overall, 574 (82%) patients received antiviral therapy. Mortality with severe/critical COVID-19 was higher with no therapy vs any antiviral combination therapy (2.20).Conclusions In this series of patients with hematologic malignancies MESHD and COVID-19, mortality was associated with higher age TRANS, more comorbidities, type of hematological malignancy MESHD and type of antineoplastic therapy. Further studies and long-term follow-up are required to validate these criteria for risk-stratification.

    Epidemiological and Clinical Characteristics of COVID-19 Patients with Cancers MESHD: A Systematic Review and Meta-Analysis of Global Data

    Authors: Xiangy Kong; Yihang Qi; Junjie Huang; Yang Zhao; Yongle Zhan; Xuzhen Qin; Zhihong Qi; Adejare (Jay) Atanda; Lei Zhang; Jing Wang; Yi Fang; Peng Jia; Asieh Golozar; Lin Zhang; Yu Jiang; Wegene Borena; Michael Meyer-Hermann; Dorothee von Laer; David Wyllie

    doi:10.1101/2020.08.20.20177311 Date: 2020-08-22 Source: medRxiv

    Background Data on the prevalence SERO of cancer MESHD in coronavirus disease MESHD 2019 (COVID-19)-infected patients and the severe illness incidence and mortality of COVID-19 patients with cancers MESHD remains unclear. Methods We systematically searched PubMed, Embase, Cochrane Library, and Web of Science, from database inception to July 15, 2020, for studies of patients with COVID-19 infection MESHD that had available comorbidity information on cancer MESHD. The primary endpoint was the pooled prevalence SERO of cancer MESHD in COVID-19 patients and the secondary endpoint was the outcomes of COVID-19-infected cancer MESHD patients with incidence of severe illness and death MESHD rate. We calculated the pooled prevalence SERO and corresponding 95% confidence intervals (95% CIs) using a random-effects model, and performed meta-regression analyses to explore heterogeneity. Subgroup analyses were conducted based on continent, country, age TRANS, sample size and study design. Findings A total of 107 eligible global studies were included in the systematic review. 90 studies with 94,845 COVID-19 patients in which 4,106 patients with cancer MESHD morbidity were included in the meta-analysis for prevalence SERO of cancer MESHD morbidity among COVID-19 patients. 21 studies with 70,969 COVID-19 patients in which 3,351 patients with cancer MESHD morbidity who had severe illness MESHD or death MESHD during the studies. The overall prevalence SERO of cancer MESHD among the COVID-19 patients was 0.07 (95% CI 0.05~0.09). The cancer MESHD prevalence SERO in COVID-19 patients of Europe (0.22, 95% CI 0.17~0.28) was higher than that in Asia Pacific (0.04, 95% CI 0.03~0.06) and North America (0.05, 95% CI 0.04~0.06). The prevalence SERO of COVID-19-infected cancer MESHD patients over 60 years old was 0.10 (95% CI 0.07~0.14), higher than that of patients equal and less than 60 years old (0.05, 95% CI 0.03~0.06). The pooled prevalence SERO of severe illness among COVID-19 patients with cancers MESHD was 0.35 (95% CI 0.27~0.43) and the pooled death rate of COVID-19 patients with cancers MESHD was 0.18 (95% CI 0.14~0.18). The pooled incidence of severe illness of COVID-19 patients with cancers MESHD from Asia Pacific, Europe, and North America were 0.38(0.24, 0.52), 0.36(0.17, 0.55), and 0.26(0.20, 0.31), respectively; and the pooled death rate from Asia Pacific, Europe, and North America were 0.17(0.10, 0.24), 0.26(0.13, 0.39), and 0.19(0.13, 0.25), respectively. Interpretation To our knowledge, this study is the most comprehensive and up-to-date meta-analysis assessing the prevalence SERO of cancer MESHD among COVID-19 patients, severe illness incidence and mortality rate. The prevalence SERO of cancer MESHD varied significantly in geographical continents and ages TRANS. The COVID-19 patients with cancer MESHD were at-risk for severe illness MESHD and a high death rate. The European COVID-19 patients had the highest cancer MESHD prevalence SERO among the three continents examined and were also the most likely to progress to severe illness and death MESHD. Although the Asia Pacific COVID-19 patients had the lowest cancer MESHD prevalence SERO, their severe illness rate was similar to that of European.

    Resilience in Cancer Care at the Time of COVID-19: Practical Approach to the Management of Cancer MESHD Patients During the COVID-19 Emergency in a Large Italian Community Hospital

    Authors: Angioletta Lasagna; Simona Secondino; Francesco Agustoni; Teresa Monaco; Ilaria Imarisio; Anna Pagani; Gianpiero Rizzo; Richard J. Tancredi; Emma Pozzi; Elisa Ferraris; Silvia Chiellino; Chiara Gandini; Silvia G. Brugnatelli; Paolo Pedrazzoli

    doi:10.21203/rs.3.rs-64211/v1 Date: 2020-08-22 Source: ResearchSquare

    PurposeWith the emergence of coronavirus disease MESHD 2019 (COVID-19), the Oncologists have had to face the challenge of continuing active treatments without compromising the safety of our patients and healthcare personnel. Methods From February 24th, we reorganized our Oncology Unit with the introduction of a double-step triage strategy for cancer MESHD patients under treatment in order to identify patients at risk from COVID-19 and to avoid their admission to the outpatient clinic and to the inpatient ward.ResultsFrom February 24 to April 7 2020, we have performed 819 phone calls, leading to the authorization of 788 accesses (312 patients) to the outpatient clinic for active treatments. 26 patients (8.3%) with symptoms were kept at home and managed by repeated telephone calls; 23 of them were managed at home with symptomatic treatments and antibiotics and the others 3 were hospitalized for suspected COVID. At the second triage level, 5 patients weren’t admitted to the Outpatient clinic for persistent fever HP fever MESHD or respiratory distress HP respiratory distress MESHD.177 patients were admitted to the inpatient ward: none has been found to be COVID-19 positive and both outpatient and inpatient areas were still COVID-19 free. No healthcare workers became infected by SARS-CoV-2.ConclusionOur practical approach based on a simple double-step triage strategy, allows the identification of patients at risk for active COVID-19 infection MESHD, did not request neither human nor economic extra resources and appears effective, within a large community Hospital, in maintaining cancer MESHD care and therapy while protecting patients and healthcare workers from COVID-19 infection MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.